Latest other current liabilities for ENTA: $6.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Enanta Pharmaceuticals (ENTA) currently reports a other current liabilities of $6.9M as of March 2026. That compares with $34M in the prior-year period — down 80.0% year over year. Use the charts on this page to explore Enanta Pharmaceuticals's other current liabilities history and peer comparisons.
Enanta Pharmaceuticals's other current liabilities decreased from $34M to $6.9M — a 80.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Enanta Pharmaceuticals reported $6.9M in other current liabilities as of March 2026. That compares with $34M in the prior-year period — down 80.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current other current liabilities of $6.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enanta Pharmaceuticals, and consider following ENTA for alerts when major investors trade the stock.
Enanta Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $6.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTA with unrelated industries.